Risedronic Acid Concept

subject area of

• 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.  Academic Article
• In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada  Academic Article
• Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee  Academic Article
• Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis  Academic Article
• Cost-effectiveness of alternative treatments for women with osteoporosis in Canada  Academic Article
• Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada  Academic Article
• Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada  Academic Article
• Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial  Academic Article
• Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study  Academic Article
• Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate  Academic Article
• Efficacy of risedronate on clinical vertebral fractures within six months  Academic Article
• Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women  Academic Article
• Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis  Academic Article
• III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis  Academic Article
• Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis  Academic Article
• Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study  Academic Article
• Oral bisphosphonates  Academic Article
• Osteonecrosis of the jaw: new developments in an old disease.  Academic Article
• Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy  Academic Article
• Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis  Academic Article
• Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate  Academic Article
• Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.  Academic Article
• Risedronate for the prevention and treatment of postmenopausal osteoporosis.  Academic Article
• The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis  Academic Article
• Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease  Academic Article
• Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?  Academic Article
• Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data  Academic Article
• [Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].  Academic Article